TCGA-YF-AA3M-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.63337714
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.670
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.590
- MYC_TARGETS_V2+0.580
- MITOTIC_SPINDLE+0.390
- DNA_REPAIR+0.380
- MTORC1_SIGNALING+0.370
- OXIDATIVE_PHOSPHORYLATION+0.350
- ESTROGEN_RESPONSE_LATE+0.260
- PI3K_AKT_MTOR_SIGNALING+0.260
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.380
- ALLOGRAFT_REJECTION-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- NOTCH_SIGNALING-0.300
- IL2_STAT5_SIGNALING-0.280
- INFLAMMATORY_RESPONSE-0.280
- WNT_BETA_CATENIN_SIGNALING-0.250
- INTERFERON_ALPHA_RESPONSE-0.240
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.882 |
| 2 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.880 |
| 3 | TCGA-CV-7180-01A-11R-2016-07 | — | — | 0.878 |
| 4 | TCGA-77-8144-01A-11R-2247-07 | — | cohortSQ1 | 0.860 |
| 5 | TCGA-94-8035-01A-11R-2247-07 | — | cohortSQ1 | 0.853 |
| 6 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.849 |
| 7 | SRR1516051 | — | — | 0.848 |
| 8 | SRR26320071 | — | — | 0.847 |
| 9 | MNG1063 | — | — | 0.843 |
| 10 | SRR35579804 | — | C | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.670 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |